122433-41-4

Usage

Uses

Used in Scientific Research:
METHYL 5-BROMO-2-METHOXYNICOTINATE 98%METHYL 5-BROMO-2-METHOXY-3-PYRIDINECARBOXYLATE is used as a chemical standard for calibration of laboratory equipment and testing procedures. Its high purity and stable structure make it a reliable reference material in various analytical processes.
Used in Industrial Manufacturing:
METHYL 5-BROMO-2-METHOXYNICOTINATE 98%METHYL 5-BROMO-2-METHOXY-3-PYRIDINECARBOXYLATE is used as a raw material or intermediate in the synthesis of various chemical products. Its unique chemical properties, such as the presence of bromine and a pyridine ring, contribute to the development of new compounds and materials in the industry.

Upstream product

• 67-56-1 methanol 
• 54916-66-4 5-bromo-2-methoxy-nicotinic acid 
• 124-41-4 sodium methylate 
• 78686-79-0 methyl 2-chloro-5-bromonicotinate 
• 29241-65-4 5-bromo-2-chloronicotinic acid 
• 104612-36-4 5-bromo-2-hydroxynicotinic acid 
• 609-71-2 2-hydroxy-3-carboxypyridine 
• 120034-05-1 5-bromo-2-oxo-1,2-dihydropyridine-3-carboxylic acid methyl ester 

Downstream Products

• 888499-96-5 C₁₁H₁₃NO₃ 
• 1083168-93-7 methyl 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carboxylate 
• 351410-47-4 (5-bromo-2-methoxy-pyridin-3-yl)-methanol 
• 103058-87-3 5-bromo-2-methoxypyridine-3-carboxaldehyde 

Relevant academic research and scientific papers

Nitrogen-containing heterocyclic compound as well as preparation method, pharmaceutical composition and application thereof

The invention provides a nitrogen-containing heterocyclic compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound as shownin a formula I which is described in the specification,

NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.

PPAR AGONIST COMPOUNDS, PREPARATION AND USES

The present invention relates to novel PPAR agonist compounds as well as pharmaceutical compositions containing them. The compounds according to the invention are of quite particular therapeutic interest, notably for treating diabetes and/or dyslipidemias, as well as for preventing cardiovascular pathologies.

HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS

The invention relates to chemical compounds of formula (IB): or a salt thereof. In some embodiments, the invention relates to inhibitors of UDP-3-0 — (R-S-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein and their use in the prevention and/or treatment of Gram- negative bacterial infections.

N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS

Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can

PYRIDINE N-OXIDES AS ANTIVIRAL AGENTS

The present invention relates to pyridinone derivatives of formula (I) wherein Z represents C2-6 alkynyl, aryl or heteroaryl, any of which groups may be optionally substituted, and R1 represents hydrogen, C1-6alkyl, C

Azolidinedione derivatives

A series of novel spiro-deteroazolones derived from a 2,3-dihydropryrano[2,3-b]pyridine ring system have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical member compounds include spiro-imides, spiro-oxazolidinediones, spiro-thiazolidinediones and spiro-imidazolidinediones derived from the aforesaid ring system. (4'S) (2'R)-6'-Chloro-2',3'-dihydro-2'-methyl-spiro-[imidazolidine-4,4'-4'H-pyrano[2,3-b]pyridine]-2,5-dione represents a typical and preferred member compound. Methods for preparing all these compounds from known starting materials are provided.

Spiro hydantoin aldose reductase inhibitors derived from 8-aza-4-chromanones

A series of spiro hydantoins derived from 8-azachromanones (2,3-dihydro-4H-pyrano[2,3-b]pyridin-4-ones) has been prepared and tested for aldose reductase inhibitory activity. The standard Bucherer-Bergs conditions had to be drastically modified to increas

Azolidinedione derivatives

Spiro-heteroazolones of formula wherein, Z is methylene, oxygen, sulfur or imino; Y is oxygen or sulfur; and -A=B-D=E- represents -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH or -CH=CH-CH=N-, or an N-oxide derivative thereof. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical member compounds include spiro-imides, spiro-oxa-zolidinediones, spiro-thiazolidinediones and spiro-imidazolidinediones derived from the aforesaid ring system. (4'S)(2'R)-6'-Chloro-2',3'-dihydro-2'-methyl--spiro-[imidazolidine-4,4'-4'H-pyrano[2,3-b]pyridine]--2,5-dione represents a typical and preferred member compound. Methods for preparing all these compounds from known starting materials are provided.